Before joining Charles River as Executive Director BD Early Discovery, Ronald drove the innovation & technology strategy for companies like Sanofi and Takeda. At PA Consulting, he led projects for some of the World’s top 10 pharmaceutical companies around strategy, commercialization, and digital. At his company BioFrontline, Ronald provides management, strategy, and commercial advice to life sciences companies in the United States, Europe and Asia. Ronald obtained MAs in biotechnology and molecular biology and a Ph.D. in microbiology before spending six years at Harvard studying Parkinson’s disease, schizophrenia, and the genetics of aggressive behavior. He then transitioned to industry working with companies ranging from start-ups to global pharma and biotech companies. Ronald has been following the AI field for over 10 years and is frequently invited to deliver national and international presentations on this topic. His LinkedIn groups ‘AI –– Artificial Intelligence,’ ‘Small Molecules,’ ‘Boston Biotech,’ and ‘Golden Triangle Biotech’ –– serve over 15,000 members.
.svg)
